Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays
Open accessThe DOI matches its Crossref record; 309 of the 334 references it cites were found in a registry or an index; 163 of the 299 sources its claims cite were checked for support.
Abstract
Inherited retinal dystrophies and optic neuropathies cause chronic disabling loss of visual function. The development of recombinant adeno-associated viral vectors (rAAV) gene therapies in all disease fields have been promising, but the translation to the clinic has been slow. The safety and efficacy profiles of rAAV are linked to the dose of applied vectors. DNA changes in the rAAV gene cassette affect potency, the expression pattern (cell-specificity), and the production yield. Here, we present a library of rAAV vectors and elements that provide a workflow to design novel vectors. We first performed a meta-analysis on recombinant rAAV elements in clinical trials (2007–2020) for ocular gene therapies. We analyzed 33 unique rAAV gene cassettes used in 57 ocular clinical trials. The rAAV gene therapy vectors used six unique capsid variants, 16 different promoters, and six unique polyadenylation sequences. Further, we compiled a list of promoters, enhancers, and other sequences used in current rAAV gene cassettes in preclinical studies. Then, we give an update on pro-viral plasmid backbones used to produce the gene therapy vectors, inverted terminal repeats, production yield, and rAAV safety considerations. Finally, we assess rAAV transgene and bioactivity assays applied to cells or organoids in vitro, explants ex vivo, and clinical studies.
Overview
CoChat Summary
TL;DR
This review/meta-analysis catalogs recombinant AAV vector elements used in ocular gene therapy clinical trials (2007–2020) and preclinical assays, analyzing 33 unique rAAV gene cassettes from 57 trials. It provides a workflow/library of capsids, promoters, enhancers, introns, polyadenylation sequences, production considerations, and transgene/bioactivity assay models for designing ocular rAAV vectors.
Key findings
- The meta-analysis identified 33 unique rAAV gene cassettes used in 57 ocular clinical trials; these used six unique capsid variants, 16 different promoters, and six unique polyadenylation sequences.
- Five different AAV-RPE65 products were tested in 13 clinical trials, leading to the first retinal gene therapy approved by the FDA in December 2017 and EMA in November 2018 (AAV-hRPE65v2; voretigene neparvovec-rzyl, LUXTURNA).
- The review compiles vector elements including capsids, ubiquitous and cell-specific promoters, enhancers, introns, WPRE, polyadenylation sequences, pro-viral plasmid backbones, ITRs, and production platforms; it notes rAAV packaging capacity of about 4.5–4.6 kb excluding ITRs, while scAAV reduces capacity to a maximum of 2.5 kb including ITRs.
- Assay models reviewed include in vitro cell lines, hiPSC-derived RPE, retinal organoids, ex vivo human retina, and in vivo/NHP studies; NHP and human retinal explants matched more closely (correlation r = 0.66–0.67) than mouse/human comparisons (r = 0.24–0.32).
Methods
- Meta-analysis: clinical trial identifiers were collected from reviews on ocular gene therapy, then searched on clinicaltrials.gov using keywords including AAV, gene therapy, retinitis pigmentosa, RP, Leber congenital amaurosis, LCA, AMD, and CHM, with last search date 01 April 2020; the search was limited to ocular gene therapies and cross-checked against news, reviews, Ph.D. theses, patents, SEC filings, company websites, presentations, and conference abstracts.
- The 33 unique rAAV ocular gene therapy products were analyzed for prokaryotic plasmid backbone, ITR AAV serotype, enhancers, promoters, introns, cDNA genes, codon optimization, human or other species-related sequences, post-transcriptional stabilizing sequences, polyadenylation sequences, and rAAV production platform; missing information was indicated as “UntoldR” or “?”.
- The paper also compiles preclinical promoters, enhancers, and other sequences and reviews transgene expression assays and biological activity assays across in vitro, ex vivo, and in vivo models.
Limitations
- The paper states that many papers on rAAV ocular trials do not sufficiently describe the elements on the plasmid used for viral vector production, including bacterial origin and bacterial selection markers, and that poor description and the vast expanse of rAAV vectors make fair comparison of vector elements very challenging.
- The paper states that large-scale comparative rAAV element studies are missing in ophthalmology; it also notes that rAAV integration studies in the retina are underrepresented and that almost no rAAV study specifically investigated rAAV integration events.
- Evident from the text: as a review/meta-analysis, it does not report new primary experimental data, and missing or incomplete source information is marked as “UntoldR” or “?”, indicating reliance on secondary and sometimes incomplete public/company documentation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 How to assess Inverted Terminal Repeats (ITRs) of rAAV and how they allow concatemerization. (A) Restriction enzyme sites in the AAV serotype 2 ITR in the flop configuration. RBE’/RBE binds Rep68 (RBE, Rep-binding element) and initiates the Rep helicase. The Rep helicase nicks the trs (terminal resolution site). Restriction enzyme recognition site indicated in blue and the actual cut in red. Figure adapted from [238]. (B) ITR structure in the nucleus after second-strand DNA synthesis in dividing cells favoring homologous recombination. Most rAAV-vectors form episomal concatemeric circular double-stranded DNA.](https://figures.cochat.ai/paper-figures/d2cf029bfc5c418988eb657099b1a410/recombinant-adeno-associated-viral-vectors-raav-vector-elements-in-ocular-gene-figure-4.jpg)
![Figure 5 A hypothetical model of the spread of rAAV capsids (serotypes 1, 2, 5 8, and 9) after intravitreal or subretinal injection in disease or non-disease mouse retinas in vivo based on the studies [99,294,304,306,308,309]. RPE, retinal pigment epithelium; OLM, outer limiting membrane, ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; GCL, ganglion cell layer; ILM, Inner Limiting Membrane.](https://figures.cochat.ai/paper-figures/e3f5847ede504cb38d2d032ab640db72/recombinant-adeno-associated-viral-vectors-raav-vector-elements-in-ocular-gene-figure-5.jpg)

Verification
Claims the paper makes
109 Valid · 57 Not valid · 98 Not checked · 102 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Relative tissue-specific expression of two gRNAs for CRISPR/Cas gene editing in myotubes was achieved by linking a muscle-specific MHCK7 promoter (pol II) with gRNA-linked self-cleaving ribozyme sequences derived of Hepatitis delta virus (HDV) and a Hammerhead (HH) sequence [134-137].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 3.5. Small Nuclear RNA (snRNA) Promoters
What the sources say
- Partly supportedcites [134] Eckenfelder, 2012, The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery, Mol. Ther. Nucleic Acids sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [135] Salva, 2007, Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle, Mol. Ther. source
- Disputedcites [136] LaVail, 2000, Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) describes a different construct: rAAV vectors used a proximal bovine rod opsin promoter to express hairpin or hammerhead ribozymes in rat photoreceptors. Those ribozymes targeted mutant rhodopsin transcripts; the paper does not describe MHCK7-driven, HDV/hammerhead-flanked CRISPR gRNAs in myotubes. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [137] 110. Xu, L.; Zhao, L.; Gao, Y.; Xu, J.; Han, R. Empower multiplex cell and tissue-specific CRISPR-mediated gene manipulation with self-cleaving ribozymes and tRNA. Nucleic Acids Res. 2017, 45. [CrossRef] 138. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, if left active in cells, functional rAAV-CRISPR/Cas9 systems do increase the number of off-target integration events into the genome [218].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 4.3. rAAV-Vectors Expressing CRISPR/Cas
What the sources say
- Disputedcites [218] 136. Hanlon, K.S.; Kleinstiver, B.P.; Garcia, S.P.; Zaborowski, M.P.; Volak, A.; Spirig, S.E.; Muller, A.; Sousa, A.A.; Tsai, S.Q.; Bengtsson, N.E.; et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat. Commun. 2019, 10. [CrossRef] sourceExperimental — accuracy not yet measured
The Results (Genome-wide AAV mapping from mouse brain) report no increase in the overall number of integration sites when Cas9 and gRNA were both present, and say integration at predicted off-target cut sites was below detection. The Discussion likewise reports no significant increase in overall AAV integration with Cas9; the increase was at CRISPR target sites, not off-target sites. The paper raises sustained nuclease activity as a potential concern but does not report the claimed off-target increase. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Because of the relatively large size of 4277 bp of dCas9-VPR cDNA, the authors used a dual rAAV system to express the dCas9-VPR and gRNA expression cassettes [223,224].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 4.3. rAAV-Vectors Expressing CRISPR/Cas
What the sources say
- Disputedcites [223] 223. Perez-Pinera, P.; Kocak, D.D.; Vockley, C.M.; Adler, A.F.; Kabadi, A.M.; Polstein, L.R.; Thakore, P.I.; Glass, K.A.; Ousterout, D.G.; Leong, K.W.; et al. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat. Methods 2013, 10, 973-976. [CrossRef] [PubMed] sourceExperimental — accuracy not yet measured
The paper’s Online Methods (Plasmids; Cell culture and transfection, page unavailable) describe a dCas9-VP64 construct and transfection of plasmids encoding dCas9-VP64 and gRNAs, not a dual rAAV system expressing dCas9-VPR. Our copy does not give a 4277-bp dCas9-VPR cDNA size or attribute the delivery method to that size. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Disputedcites [224] 224. Konermann, S.; Brigham, M.D.; Trevino, A.E.; Joung, J.; Abudayyeh, O.O.; Barcena, C.; Hsu, P.D.; Habib, N.; Gootenberg, J.S.; Nishimasu, H.; et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 2015, 517, 583-588. [CrossRef] [PubMed] sourceExperimental — accuracy not yet measured
The Extended Data Figure 7 caption describes three lentiviral vectors expressing sgRNA, dCas9-VP64, and MS2-p65-HSF1, not a dual rAAV system expressing dCas9-VPR and gRNA. The genome-scale gene activation screen section likewise identifies the delivery system as lentiviral. These passages do not give a 4277-bp dCas9-VPR cDNA size. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The hypoxia-induced Müller glial specific promoter showed no luciferase expression in HEK293, C6, HT22, and ARPE19 cells [97].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 5.1. In Vitro Immortalized Epithelial Cell Lines for Transgene and Bioactivity Assays
What the sources say
- Disputedcites [97] 97. Prentice, H.M.; Biswal, M.R.; Dorey, C.K.; Blanks, J.C. Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease. Investig. Ophthalmol. Vis. Sci. 2011, 52, 8562-8570. [CrossRef] [PubMed] sourceExperimental — accuracy not yet measured
The Figure 4 caption says the regulated promoter had basal or minimal expression in HEK, C6, HT22, and ARPE-19 cells, not no expression. The Hypoxic Induction and Cell Specificity section reports no hypoxic induction in those lines; that does not establish an absence of luciferase expression. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The ubiquitous UbC promoter showed no toxicity to the mouse RPE [324].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 5.6.4. Cis-Regulatory Toxicity of rAAV Vectors In Vivo?
What the sources say
- Disputedcites [324] Xiong, 2019, AAV cis-regulatory sequences are correlated with ocular toxicity, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Results section on RPE toxicity says the broadly active UbiC promoter induced strong RPE toxicity, the opposite of the claim. The study used subretinal AAV injections in mice, as described in the Results section on photoreceptor toxicity. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
203 more claims · 84 with their cited sources checked
Create a free account to see all 366 claims and to verify the 3 references still open.
- It may state two separate claims as one. 107
- Probably not a substantial claim. 78
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The immune reactions include induction of neutralizing antibodies that reduce the number of capsids reaching the target cells, innate immune pathways silencing the gene cassette within the host cell, and cell-mediated T-cell immune responses against foreign protein expression.”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike adenoviruses, AAVs generate relatively mild innate and adaptive immune responses, which allow for stable long-term transgene expression.”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 2. Ocular rAAV Vector-Based Therapies in Clinical Trials
“a promoter shortened to 750 bp (NA65p)”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 7.1. A Meta-Analysis on Pro-Viral Plasmids and Production Platforms for Ocular rAAV Therapies in Clinical Trials
“| NA65p | 1383 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > Additional information
“Lentiviral products, cell therapy products, antibodies, and antisense oligonucleotide (AONs) products were removed from Figure 3 and Table 1 to include only rAAV-based therapies.”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 7.1. A Meta-Analysis on Pro-Viral Plasmids and Production Platforms for Ocular rAAV Therapies in Clinical Trials
“| Usher | | UshStat | EIAV | CMV | | WPRE | MYO7A | SIN-LTR | HEK293 | | Usher | | QR-421a | | | | AON-USH2A | | | Synthetic |”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Sun, 2010, Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations, Gene Ther., 17, 117, 10.1038/gt.2009.104”
Cited work 10.1038/gt.2009.104 · retracted 2024-11-15 · notice 10.1038/s41434-024-00505-6 · this paper published 2020-06-12
Citations
Cites
1 retracted
Sun, X., Pawlyk, B., Xu, X., Liu, X., Bulgakov, O. V., Adamian, M., Sandberg, M. A., Khani, S. C., Tan, M.-H., Smith, A. J., et al. (2010) · Gene Therapy · doi:10.1038/gt.2009.104 · Cited by 123
RetractedEfficient selection for high-expression transfectants with a novel eukaryotic vector
Hitoshi, N., Ken-ichi, Y., & Jun-ichi, M. (1991) · Gene · doi:10.1016/0378-1119(91)90434-d · Cited by 5,134
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825 · cited 1×
“Because of the relatively large size of 4277 bp of dCas9-VPR cDNA, the authors used a dual rAAV system to express the dCas9-VPR and gRNA expression cassettes [223,224].”
BackgroundAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“Dose finding studies have shown that a high number of rAAV particles (>1012 viral genomes (vg)) can give rise to transient inflammation in mice [35].”
BackgroundSTEROID RECEPTOR REGULATED TRANSCRIPTION OF SPECIFIC GENES AND GENE NETWORKS
Yamamoto, K. R. (1985) · Annual Review of Genetics · doi:10.1146/annurev.ge.19.120185.001233 · Cited by 1,872 · cited 1×
“Active when glucocorticoids or progestins present [175,176]”
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677 · cited 1×
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
BackgroundDynan, W. S., & Tjian, R. (1983) · Cell · doi:10.1016/0092-8674(83)90210-6 · Cited by 1,445 · cited 1×
“For example, the transactional activation of the widely used CMV or early SV40 promoters is related to the binding of the ubiquitous transcription factors Sp1/Sp3 [92,93].”
MethodPurification and biochemical characterization of the promoter-specific transcription factor, Sp1
Briggs, M. R., Kadonaga, J. T., Bell, S. P., & Tjian, R. (1986) · Science · doi:10.1126/science.3529394 · Cited by 1,435 · cited 1×
“Moreover, most mammalian cells express the Sp1 transcription factor [94].”
BackgroundConvection-enhanced delivery of macromolecules in the brain.
Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., & Oldfield, E. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2076 · Cited by 1,415 · cited 1×
“MVM Ubiquitous, ++ [54,67] MeCP2 229 ubiquitous [68] CMV 800 Ubiquitous, ++, prone to silencing [54] shCMV 220 Ubiquitous, ++ [24]”
Research works printed but not linked: 8
- 11. Fahim, A.T.; Daiger, S.P.; Weleber, R.G. Nonsyndromic Retinitis Pigmentosa Overview. Available online: http://www.ncbi.nlm.nih.gov/pubmed/20301590 (accessed on 19 January 2017).
- 34. Lei, B.; Zhang, K.; Yue, Y.; Ghosh, A.; Duan, D. Retinal Degenerative Diseases; Spring: New York, NY, USA, 2010; Volume 664, pp. 671-678.
- 126. Dona, M.A. Gene therapy using miniUSH2A genes improves visual function in a zebrafish ush2a knock-out model. In Towards gene therapy for USH2A-associated retinitis pigmentosa. ~Fishing for answers~[Doctoral Thesis];
- 127. Kremer, J.M.J., Keunen, J.E.E., van Wijk, H.A.R., Eds.; Radboud University Nijmegen: Nijmegen, The Netherlands, 2018; pp. 1-243, ISBN 978-94-6375-060-8. 188.
- 2017, The pathway from genes to gene therapy in glaucoma: A review of possibilities for using genes as glaucoma drugs, Asia-Pacific J. Ophthalmol., 6, 80
- Ceiler, J., Afzal, S., Leuchs, B., Fronza, R., Lulay, C., Büning, H., Schmidt, M., and Gil-Farina, I. (2017, January 10). Wild-Type and Recombinant AAV Integration in Human Cardiomyocytes: Focus on Mitochondrial Genome. Proceedings of the AAV Vector Biology, Available online: https://www.researchgate.net/publication/316699961_Wild-Type_and_Recombinant_AAV_Integration_in_Human_Cardiomyocytes_Focus_on_Mitochondrial_Genome.
- Couto, 2016, Poster C0048 ARVO: Potency Assay for AAV Vector Encoding Retinal Pigment Epithelial 65 Protein, Investig. Ophthalmol. Vis. Sci., 57, 1
- 151. Akl, M.R.; Nagpal, P.; Ayoub, N.M.; Tai, B.; Prabhu, S.A.; Capac, C.M.; Gliksman, M.; Goy, A.; Suh, K.S. Molecular and clinical significance of fibroblast growth factor 2 (FGF2/bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget 2016, 7, 44735-44762. [CrossRef] 287. ThermoScientific Growth Factors in HyClone Cell Culture Serum. Available online: https://static. thermoscientific.com/images/D22225~{}.pdf (accessed on 11 June 2020). 288.
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“116 Another study reported that a fragment of the mouse methyl-CpG-binding protein-2 promoter enabled robust long-term expression speci fi cally in neurons.”
BackgroundGene therapy advances: A meta-analysis of AAV usage in clinical settings
Au, H. K. E., Isalan, M., & Mielcarek, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.809118 · Cited by 284
“Selecting the right capsid and promoter is the first step to improve targeted cell transduction and expression (2, 15).”
BackgroundAAV vector development, back to the future
Suárez-Amarán, L., Song, L., Tretiakova, A. P., Mikhail, S., & Samulski, R. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.064 · Cited by 104
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“The immune reactions include induction of neutralizing antibodies that reduce the number of capsids reaching the target cells, innate immune pathways silencing the gene cassette within the host cell, and cell-mediated T-cell immune responses against foreign protein expression.(18)”
BackgroundNieuwenhuis, B., Laperrousaz, E., Tribble, J. R., Verhaagen, J., Fawcett, J. W., Martin, K. R. G., Williams, P. A., & Osborne, A. (2023) · Gene Therapy · doi:10.1038/s41434-022-00380-z · Cited by 89
Achberger, K., Cipriano, M., Duechs, M. J., Schön, C., Michelfelder, S., Stierstorfer, B., Lamla, T., Kauschke, S. G., Chuchuy, J., Roosz, J., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.08.008 · Cited by 81
“7m8 were chosen, as they are currently applied in clinical trials or approved retinal therapy (Buck and Wijnholds, 2020; Shahryari et al., 2019).”
MethodAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
Chan, Y. K., Dick, A. D., Hall, S. M., Langmann, T., Scribner, C. L., Mansfield, B. C., & for the Ocular Gene Therapy Inflammation Working Group (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.4.3 · Cited by 56
Potency testing of cell and gene therapy products
Salmikangas, P., Carlsson, B., Klumb, C., Reimer, T., & Thirstrup, S. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1190016 · Cited by 59
“Factors impacting biological activity like vector tropism, choice of the promoter, vector infectivity and selectivity of the transgene expression (when using conditional or cell type-specific promoters) need to be addressed as well and taken into account in the product design (6, 27).”
BackgroundGenetics, pathogenesis and therapeutic developments for Usher syndrome type 2
Stemerdink, M., García‐Bohórquez, B., Schellens, R. T. W., García‐García, G., van Wijk, E., & Millán, J. M. (2021) · Human Genetics · doi:10.1007/s00439-021-02324-w · Cited by 49
Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
Tropism of AAV Vectors in Photoreceptor-Like Cells of Human iPSC-Derived Retinal Organoids
McClements, M. E., Steward, H., Atkin, W., Goode, E. A., Gándara, C., Chichagova, V., & MacLaren, R. E. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.4.3 · Cited by 36
Gene therapy for mitochondrial disorders
Keshavan, N., Minczuk, M. A., Viscomi, C. F., & Rahman, S. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12699 · Cited by 43
“Transgene expression is therefore determined by several variables including the species/strain of the subject, 44 route of delivery, 45 age at delivery, 46 serotype of AAV, promoter 47 and dose.”
BackgroundSobh, M., Lagali, P. S., Ghiasi, M., Montroy, J. R., Dollin, M. L., Hurley, B. R., Leonard, B. C., Dimopoulos, I. S., Lafreniere, M., Fergusson, D. A., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.11.24 · Cited by 38
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
Research Models and Gene Augmentation Therapy for CRB1 Retinal Dystrophies
Boon, N., Wijnholds, J., & Pellissier, L. P. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00860 · Cited by 36
Self-citationVoretigene Neparvovec and Gene Therapy for Leber’s Congenital Amaurosis: Review of Evidence to Date
Padhy, S. K., Takkar, B., Narayanan, R., Venkatesh, P., & Jalali, S. (2020) · The Application of Clinical Genetics · doi:10.2147/tacg.s230720 · Cited by 39
The Ocular Gene Delivery Landscape
Sahu, B., Chug, I., & Khanna, H. (2021) · Biomolecules · doi:10.3390/biom11081135 · Cited by 28
Fakhiri, J., & Grimm, D. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.005 · Cited by 30
Botto, C., Dalkara, D., & El-Amraoui, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.737632 · Cited by 32
“This groundbreaking advancement of RPE65 gene therapy paved the way for numerous breakthrough clinical phase I/II trials exploring gene replacement for monogenic recessive diseases of the retina, such as choroideremia, retinoschisis, achromatopsia, Usher syndrome, and Leber hereditary optic neuropathy (Buck and Wijnho…”
BackgroundCell-specific regulation of gene expression using splicing-dependent frameshifting
Ling, J. P., Bygrave, A. M., Santiago, C. P., Carmen‐Orozco, R. P., Trinh, V., Yu, M., Li, Y., Liu, Y., Bowden, K. D., Duncan, L. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33523-2 · Cited by 33
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa
de la Cámara, C. M.-F., Cehajic‐Kapetanovic, J., & MacLaren, R. E. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2152003 · Cited by 31
“The promoter sequence used in the gene therapy vector can also include enhancers such as transcription factor-binding sites, nuclear localization signals or other elements to boost transcription and to increase the level of expression of the therapeutic transgene in the target cells [42,43].”
BackgroundGreen, E. A., & Lee, K. H. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.06.025 · Cited by 28
Yuan, Y., Wang, L., Zhao, X., Wang, J., Zhang, M.-S., Ma, Q.-H., Wei, S., Yan, Z., Cheng, Y., Chen, X., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12334 · Cited by 24
“Because rAAV vectors are increasingly popular tools for the biotherapeutic landscape, especially in gene therapy applications, and the rAAV serotype 9 showed highly effective penetration of the blood-brain barrier to transduce astrocytes [56, 57], we constructed rAAV9 for delivery of the dCas9-HUWE1 system.”
BackgroundRecent Developments in Gene Therapy for Neovascular Age-Related Macular Degeneration: A Review
Finocchio, L., Zeppieri, M., Gabai, A., Toneatto, G., Spadea, L., & Salati, C. (2023) · Biomedicines · doi:10.3390/biomedicines11123221 · Cited by 34
“Overall, the strategic choice of promoters in nAMD gene therapy is pivotal for optimizing treatment outcomes, tailoring expression patterns to specific cell types, and achieving the desired therapeutic effects while minimizing unintended consequences [177].”
BackgroundOcular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
Banou, L., Sarrafpour, S., Teng, C. C., & Liu, J. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/hwid7537 · Cited by 30
Retina-directed gene therapy: Achievements and remaining challenges
Biber, J., Gandor, C. L. A., Bećirović, E., & Michalakis, S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108862 · Cited by 25
Newer therapeutic options for inherited retinal diseases: Gene and cell replacement therapy
Battu, R., Ratra, D., & Gopal, L. (2022) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_82_22 · Cited by 26
“[4] Certain forms of IRDs such as Stargardt disease, Usher syndrome Type 1B and LCA10 are caused by mutations in ABCA4, MYO7A, and CEP290, respectively that have cDNA that exceeds 5 kb, and these are difficult to treat with AAV.[4]”
BackgroundInfluentialSelection of viral capsids and promoters affects the efficacy of rescue of Tmprss3-deficient cochlea
Aaron, K. A., Pekrun, K., Atkinson, P. J., Billings, S. E., Abitbol, J. M., Lee, I. A., Eltawil, Y., Chen, Y.-S., Dong, W., Nelson, R. F., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.004 · Cited by 22
X-Linked Retinitis Pigmentosa Gene Therapy: Preclinical Aspects
Mansouri, V. (2022) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00602-y · Cited by 25
“In a study by Buck and Wijnholds, the advantages and disadvantages of using recombinant AAV vectors in gene therapy for eye diseases have been discussed [53].”
BackgroundInfluentialHuang, J., Li, J., Xu, X., & Li, K. (2025) · Biomolecules · doi:10.3390/biom15070940 · Cited by 21
“Cell-type-specific promoters have now been established for nearly all major retinal cell types [129].”
Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration
She, K., Su, J., Wang, Q., Liu, Y., Zhong, X., Jin, X., Zhao, Q., Xiao, J., Li, R., Deng, H., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.002 · Cited by 16
“Both retinal cell-type-specific promoters and ubiquitous promoters have been employed in gene therapy of ocular diseases.(27) In most clinical trials of gene therapy for nAMD, ubiquitous promoters, including CB7/ CAG, CMV and CAG, were used, which can drive much higher gene expression than many tissue-specific promote…”
BackgroundRiaz, S., Sethna, S., Duncan, T. E., Naeem, M. A., Redmond, T. M., Riazuddin, S. A., Riazuddin, S., Carvalho, L. S., & Ahmed, Z. M. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.017 · Cited by 15
A Comparative Analysis of Models for AAV-Mediated Gene Therapy for Inherited Retinal Diseases
Alsalloum, A., Gornostal, E. A., Mingaleva, N., Pavlov, R. E., Kuznetsova, E., Antonova, E., Nadzhafova, A., Колотова, Д. Е., Кадышев, В. В., Mityaeva, O. N., et al. (2024) · Cells · doi:10.3390/cells13201706 · Cited by 20
“Collectively, these variables necessitate careful scrutiny when employing the RO model for study of therapeutic interventions in retinal diseases [113,121].”
BackgroundEmerging therapeutic potential of adeno-associated virus-mediated gene therapy in liver fibrosis
Bu, F., Jia, P., Zhu, Y. Y., Yang, Y., Meng, H., Bi, Y., Huang, C., & Li, J. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.06.009 · Cited by 14
“It is worth noting that with the development of biotechnology, high yields of rAAV vector can be produced without contaminating cells and helper viral proteins, and it has been successfully applied in preclinical and clinical research.(31,32) Moreover, current technologies allow rAAV to be packaged and purified rapidl…”
Retinal Gene Therapy for Usher Syndrome: Current Developments, Challenges, and Perspectives
Dinculescu, A., Link, B. A., & Saperstein, D. A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000378 · Cited by 15
RPE based gene and cell therapy for inherited retinal diseases: A review
Sanie‐Jahromi, F., & Nowroozzadeh, M. H. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.108961 · Cited by 13
Wang, S., & Xiao, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052213 · Cited by 20
“In addition, gene therapy clinical trials have also employed various enhancers to increase transgene expression [117].”
Living drugs: A wonderful evolution for therapeutic applications
Chintalapati, S. S. V. V., Sang, N., Miyahara, M., Iwata, S., Nishida, K., & Miyako, E. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100193 · Cited by 13
Tsai, Y.-T., da Costa, B. L., Nolan, N. D., Caruso, S. M., Jenny, L. A., Levi, S. R., Tsang, S. H., & Quinn, P. M. J. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2651-1_29 · Cited by 12
Develop an efficient and specific AAV-based labeling system for Muller glia in mice
Gao, Y., Fang, K., Yan, Z., Zhang, H., Geng, G., Wu, W., Ding, X., Zhang, H., Zhong, N., Wang, Q., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-27013-0 · Cited by 13
“ShH10 (Buck & Wijnholds, 2020; Yao et al., 2018), and separately delivered them to the retinas of Ai9 mice by subretinal injection (Figure 2A).”
MethodOverview of analytics needed to support a robust gene therapy manufacturing process
Ramsey, J. P., Khatwani, S. L., Lin, M. J., Boregowda, R., Surosky, R. T., & Ramelmeier, R. A. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100339 · Cited by 12
Boon, N., Lu, X., Andriessen, C. A., Orlova, M. A., Quinn, P. M. J., Boon, C. J. F., & Wijnholds, J. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101128 · Cited by 12
“42 AAV-CRB2 and AAV-CRB1 transduction onto CRB1 patient retinal orga-noids prevents morphological and transcriptional aberrations.”
BackgroundSelf-citationSauter, M. M., Noel, H. R., Sinha, D., Nelson, E. C., Xiong, M. N., Gamm, D. M., & Brandt, C. R. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110478 · Cited by 10
Major, L., McClements, M. E., & MacLaren, R. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087603 · Cited by 12
“In more than one hundred clinical trials that used the AAV vector, there was no evidence of genotoxicity [65].”
BackgroundSchultz, A., Cheng, S.-Y., Kirchner, E. G., Costello, S. M., Miettinen, H. M., Chaverra, M. E., King, C., George, L., Zhao, X., Narasimhan, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-45376-w · Cited by 9
“The U1a promoter was selected based on its small size (~ 250 bp) and ability to effectively transduce cells in the central nervous system 40 .”
BackgroundMcDonald, A. J., Gallego, C., Andriessen, C. A., Orlova, M. A., Gonçalves, M. A. F. V., & Wijnholds, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010055 · Cited by 10
“In the context of retinal disease, AAV has been successfully utilized to deliver a RPE65 transgene in the first clinically available retinal gene therapy, and a number of studies have shown AAV to be an effective vehicle for supplementation of retinal genes in several disease models [2,3].”
Self-citationResidual DNA impurities in AAV vectors—nature and transcription
Jen, H., Wilkinson, P. F., Lu, X., & Zhang, W. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101503 · Cited by 10
“22,23 Current World Health Organization (WHO) recommendations for residual hcDNA in products produced from cell substrates include a maximum of 10 ng/dose and 200 bp in size.”
Matsevich, C., Gopalakrishnan, P., Chang, N., Obolensky, A., Beryozkin, A., Salameh, M., Kostic, C., Sharon, D., Arsenijévic, Y., & Banin, E. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.08.011 · Cited by 10
Jin, Y., Li, S., Jiang, Z., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.3.11 · Cited by 8
“12 It is significant to understand the natural history, clinical heterogeneity, and the correlation between genes and phenotypes of CRB1-RD for selecting appropriate patients, treatment time points, and end points.”
BackgroundKang, J., Hang, L., Zheng, W., Luo, J., Zhang, X., Song, Y., & Liu, A. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12532 · Cited by 9
Wang, Y., Chu, X., & Wang, B. (2021) · PubMed Central · doi:10.3877/cma.j.issn.2096-112x.2021.01.004 · Cited by 7
Vendomèle, J., Chauveau, G. A., Dalkara, D., Galy, A., & Fisson, S. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.191 · Cited by 6
“32 In this study, we show that the injection of AAV8 in the subretinal space of one eye induces subclinical peripheral pro-in fl ammatory T cell immune responses to the trans-gene product correlated with the transgene expression level in the eye and the periphery.”
Zhang, H., Ren, J., Li, J., Zhai, C., Mao, F., Yang, S., Zhang, Q., Liu, Z., & Fu, X. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106328 · Cited by 6
In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin
Shao, Y., Liu, C., Liao, H., Zhang, R., Yuan, B., Yang, H., Li, R., Zhu, S., Fang, X., Esteban, C. R., et al. (2024) · Genome biology · doi:10.1186/s13059-024-03283-x · Cited by 7
“Currently, several AAV serotypes have been identified and applied in both scientific research and clinical treatment [26–30].”
BackgroundOsborne, A., Khatib, T. Z., Whitehead, M., Mensah, T., Yazdouni, S., Nieuwenhuis, B., Ali, Z., Ching, J., Watt, R., Kishi, N., et al. (2025) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00003-y · Cited by 7
How Advanced are Nanocarriers for Effective Subretinal Injection?
Guan, J.-X., Wang, Y.-L., & Wang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479327 · Cited by 5
Kelley, R. A., & Wu, Z. (2023) · Vision Research · doi:10.1016/j.visres.2023.108269 · Cited by 5
Haddadzadegan, S., Mehdizdeh, N., Wang, X., Wong, T. T. L., & Miserez, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114841 · Cited by 5
The next‐generation therapies in ophthalmology for blindness worldwide
Xu, J., Zhang, C., Jiang, J., & Jin, Z. (2024) · Eye & ENT Research · doi:10.1002/eer3.4 · Cited by 3
Expression Cassette Design and Regulation of Transgene Expression
Keravala, A., & Gasmi, M. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000363 · Cited by 5
Zhang, G., Ng, F., & Chen, M. (2021) · Virology · doi:10.1016/j.virol.2021.10.002 · Cited by 3
Duarte, F. T., & Arsenijévic, Y. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101424 · Cited by 2
Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma
Azani, A., Ghassemifar, V., Mehrdad, Z., Saberivand, M., Pour, A. B., Tahmasebi, S., Gharedaghi, H., Sharafi, M., Foroozand, H., Meigoli, M. S. S., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70425 · Cited by 2
Stem cells and genetic engineering empower therapeutic development for blinding eye diseases
Zhang, C.-J., Jin, K., & Jin, Z. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99987-8.00009-6 · Cited by 3
Insights into adeno-associated virus-based ocular gene therapy: A bibliometric and visual analysis
Chen, X., Yu, Y., Nie, H., Qin, X., Bai, W., Ren, J., Yao, J., Li, J., & Jiang, Q. (2023) · Medicine · doi:10.1097/md.0000000000034043 · Cited by 2
Regulatory Elements for Gene Therapy of Epilepsy
Chesnokova, E., Bal, N. V., Alhalabi, G., & Balaban, P. M. (2025) · Cells · doi:10.3390/cells14030236 · Cited by 2
3D Quantification of Viral Transduction Efficiency in Living Human Retinal Organoids
Rogler, T. S., Salbaum, K. A., Brinkop, A. T., Sonntag, S. M., James, R. E., Shelton, E., Thielen, A., Rose, R., Babutzka, S., Klopstock, T., et al. (2025) · Small Methods · doi:10.1002/smtd.202401050 · Cited by 2
“…characteristics of the neural retina (NR), and the retinal pigment epithelium (RPE). hROs display functional properties of the retina light sensitivity and synaptic connectivity [7–11] and thus enable insights into the physiological mechanisms behind retinal development [12,13] and diseases.”
Cell-specific regulation of gene expression using splicing-dependent frameshiftingPreprint
Ling, J. P., Bygrave, A. M., Santiago, C. P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.02.481623 · Cited by 2
A New Mouse Model for Usher Syndrome Crossing Kunming Mice with CBA/J Mice
Li, S., Jiang, Y., Zhang, L., Yan, W., Wei, D., Zhang, M., Zhu, B., Chen, T., Wang, X., Zhang, Z., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148562 · Cited by 2
Upadhyay, A. K., Drag, S., Singh, P., Rajanala, K., & Arumugham, R. G. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1679619 · Cited by 1
Becker, R., Choudhury, P., Oti, M., Fouani, Y., Strobel, B., Ketterer, S., Rumpel, S., Park, J., Kreuz, S., Maier, U., et al. (2026) · iScience · doi:10.1016/j.isci.2026.115469 · Cited by 1
“…enhancer-promoter combinations have been developed for pre-clinical and clinical studies in other target organs, such as the eye (reviewed in 21 ), the heart (reviewed in 22 ), and the CNS. 23,24 25–27 An elegant way to overcome the throughput limitations of rational design approaches is…”
Sun, Y., Xiao, D., Li, Z., Xu, D., Zhang, D., An, Y., Xue, J., Ren, Y., Liu, S., Wang, D., et al. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101646 · Cited by 2
Benefits and Shortcomings of Laboratory Model Systems in the Development of Genetic Therapies
Bucher, K., Rodríguez‐Bocanegra, E., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1757-9879
“They are required for transgene expression assays that are performed to evaluate qualitative and quantitative transgene expression [10] and for biological activity or potency assays that serve to quantitatively measure the biological activity of the transgene [11].”
BackgroundOu-Yang, H., Yang, S.-H., Chen, W., Yang, S., Cidem, A., Sung, L., & Chen, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073973
“99%) in vivo [35], which includes cruciform DNA structures at ITR-IR regions of episomes.”
BackgroundAguirre, G. K., & Beltran, W. A. (2022) · Bulletin de l Académie vétérinaire de France · doi:10.3406/bavf.2022.70996 · Cited by 1
Sun, Y., Xiao, D., Li, Z., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4640452
Li, S., Jiang, Y., Zhang, L., Yan, W., Wei, D., Zhang, M., Chen, T., Wang, X., Zhang, Z., & Su, Y. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4674394
Yu, L., Zhou, Y. F., Wang, G., Fu, J., Fu, Z., Liang, C., & Wang, J. (2024) · Molecules · doi:10.3390/molecules29225312
X-Linked Retinitis Pigmentosa Gene Therapy: Preclinical Aspects
Mansouri, V., & Bemanalizadeh, M. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009101
Becker, R., Choudhury, P., Oti, M., Fouani, Y., Strobel, B., Ketterer, S., Rumpel, S., Park, J., Kreuz, S., Maier, U., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.04.657008
“…several rationally designed cis -regulatory regions have been developed for pre-68 clinical and clinical studies in other target organs, such as the eye (reviewed in (Buck and Wijnholds 2020)), the heart (reviewed in (Schröder et al. 2023)) and the CNS (Islam and Tom 2022; Nieuwenhuis et al. 2021).”
Lundstrom, K. H. (2025) · Springer eBooks · doi:10.1007/978-3-031-77911-4_16
Ji, H., Ni, Z., Wang, F., Zhou, Y., & Sun, X. (2025) · The FASEB Journal · doi:10.1096/fj.202502453r · Cited by 1
Shao, Y., Liu, C., Liao, H.-K., Zhang, R., Yuan, B., Yang, H., Li, R., Zhu, S., Fang, X., Rodríguez-Esteban, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25893966
Shao, Y., Liu, C., Liao, H.-K., Zhang, R., Yuan, B., Yang, H., Li, R., Zhu, S., Fang, X., Rodríguez-Esteban, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26724662
Shao, Y., Liu, C., Liao, H.-K., Zhang, R., Yuan, B., Yang, H., Li, R., Zhu, S., Fang, X., Rodríguez-Esteban, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25893815
Shao, Y., Liu, C., Liao, H.-K., Zhang, R., Yuan, B., Yang, H., Li, R., Zhu, S., Fang, X., Rodríguez-Esteban, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26724665
Zhang, Y., Li, Y., Wang, Q., Pang, J., Wang, D., Yuan, T., & Liu, Z. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71287
Selecting Novel Retino-tropic AAV Capsids by Directed Evolution
Westhaus, A., & Lisowski, L. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5198-8_1
Zaydon, Y. A., Ahmed, F., & Tsang, S. H. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22193-4.00012-3
Manufacturing as biology: How T-cell processing shapes therapeutic outcomes
Przybylski, N., Zeng, Q., & Huang, X. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.05.005
Status and future of recombinant adeno‐associated virus vector manufacturing
Agbogbo, F., & Dismuke, D. J. (2026) · Biotechnology Progress · doi:10.1002/btpr.88525
“97 The regulatory RNA motifs, such as miRNA target sites (to suppress expression in off-target tissues or specific immune cell subsets), riboswitches, or other RNA stability elements, can be used to sharpen tissue specificity.”
Zhang, R., Lou, J., Jin, Z., Ou, Y., He, T., Qu, H., Yang, Y., & Qu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1822727
“…promoter from the human gene encoding α 1-antitrypsin (Laurent et al., 2025), but enters the cells in a single-stranded form, and thus requires second-strand synthesis before translation (McCarty et al., 2001; McCarty et al., 2003; McCarty, 2008; Buck and Wijnholds, 2020; Li and Samulski, 2020).”
Rothgangl, T., Carullo, N. V. N., Ohland, P., Kemptner, S., Phichith, D., & Lichinchi, G. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201833
Preclinical evaluation of AL-001, a gene therapy for wet age-related macular degeneration
Liu, X., Liu, H., Wang, L., Julia, Z., Xie, X., Jiang, L., & Zhao, C. A. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1836684
Metadata
- Authors
- Buck, T., & Wijnholds, J.
- Affiliations
- Leiden University Medical Center (NL)
- Netherlands Institute for Neuroscience (NL)
- Corresponding author
- Wijnholds, Jan
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-06-12
- Volume
- 21
- Issue
- 12
- Pages
- 4197
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7352801
- OpenAlex
- W3035416273
- Cited by
- 92
- References
- 334
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 17 · 2023: 15 · 2022: 16 · 2021: 15 · 2020: 2
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (publishedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (submittedVersion, other-oa)
- Funders
- Foundation Fighting Blindness (TA-GT-0715-0665-LUMC)
- The Netherlands Organization for Health Research and Development (43200004)
- Million Dollar Bike Ride Grant Program (MDBR-19-131-CRB1, MDBR-20-112-CRB1)
- Dutch blindness funds (Uitzicht 2013-13)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, ocular gene therapy, inherited retinal disease, optic neuropathy, promoter, inverted terminal repeats, biological activity assay, retinal organoids, clinical trials
- MeSH terms
- Dependovirus, Clinical Trials as Topic, Genetic Vectors, Optic Nerve Diseases, Promoter Regions, Genetic, Genetic Therapy, Treatment Outcome, Polyadenylation, Capsid Proteins, Retinal Dystrophies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.